Yung-Jue Bang
New Generation University College
667 Papers
5.5K Citations
Yung-Jue Bang is an academic researcher from New Generation University College. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 94, co-authored 664 publications. Previous affiliations of Yung-Jue Bang include Seoul National University Hospital & Seoul National University.
Chat about Author
Papers
Postoperative chemoradiotherapy for gallbladder cancer.
Kyu-Pyo Kim,Eui Kyu Chie,Eui Kyu Chie,Jin-Young Jang,Sun Whe Kim,Sae-Won Han,Do Youn Oh,Seock-Ah Im,Tae-You Kim,Yung-Jue Bang,Sung Whan Ha,Sung Whan Ha +11 more
TL;DR: Adjuvant chemoradiotherapy after R0 resection can achieve a good long-term survival rate in gallbladder cancer patients, even in those with lymph node metastases, and may play a role for patients who underwent R 0 resection of primary tumor without lymph node dissection.
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
Tae Yong Kim,Hye Sook Han,Keun Wook Lee,Dae Young Zang,Sun Young Rha,Young Iee Park,Jin Soo Kim,Kyung Hun Lee,Se Hoon Park,Eun Kee Song,Soo A. Jung,Na Mi Lee,Yeul Hong Kim,Jae Yong Cho,Yung-Jue Bang +14 more
TL;DR: The MTD of poziotinib combined with paclitaxel and trastuzumab was 8 mg/day and this combination yielded promising anti-tumor efficacy with manageable toxicity in previously treated patients with HER2-positive GC.
Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.
Yoojoo Lim,Jee Min Lim,Won Jae Jeong,Kyung Hun Lee,Bhumsuk Keam,Tae Yong Kim,Tae Min Kim,Sae-Won Han,Do Youn Oh,Dong Wan Kim,Tae-You Kim,Dae Seog Heo,Yung-Jue Bang,Seock-Ah Im +13 more
TL;DR: Although the general awareness of CTs was high, a relatively large proportion of patients did not have accurate knowledge; therefore, proper and accurate patient education is necessary.
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Michael F. Press,Catherine E. Ellis,Robert C. Gagnon,Tobias Grob,Marc Buyse,Ivonne Villalobos,Zhiyong Liang,Shafei Wu,Yung-Jue Bang,S. Qin,Hyun Cheol Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Karen Afenjar,Yanling Ma,Monica C. Estrada,Douglas Robinson,Stefan J. Scherer,Guido Sauter,J. Randolph Hecht,Dennis J. Slamon +21 more
TL;DR: Her2 is commonly amplified in UGI adenocarcinomas with amplification highly correlated to overexpression, and HER2 amplification levels correlated with PFS, and lapatinib-treated Asian participants and those less than 60 years had significant improvement in progression-free survival (PFS).
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
Keun Wook Lee,Dae Ho Lee,Jin Hyoung Kang,Joon Oh Park,Se Hyun Kim,Yong Sang Hong,Seung Tae Kim,Do Youn Oh,Yung-Jue Bang +8 more
TL;DR: The pharmacokinetic parameters of nivolumab were similar among patients from Korea, Japan, and the U.S. and the safety profile was consistent with findings from previous studies.